The Digital Proteome: Unveiling the Final Frontier of Biology
Prisma is advancing breakthrough protein sequencing technologies to unveil the true functional drivers of biology and transform human health.
Imagine a world where we can resolve every protein within a sample, revealing its identity and quantity with stunning resolution.
This is the future Prisma is building with unbiased, single-molecule protein sequencing, a revolutionary approach that analyzes proteins for hypothesis free discovery.
Th BioRxiv article in our featured post dives into the core of Prismas elegant protein sequencing technology. Our Universal Recognizer is a single, small molecule dye that binds directly to the N-terminus of proteins and produces a distinct optical fingerprint for each amino acid and post-translational modification. Combined with our cutting-edge, light-based sequencing approach, Prisma generates accurate amino acid sequences to enable unbiased, proteome-scale identification and quantification of proteins at the single-molecule level.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
What industry is Prisma in?
Prisma operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Prisma based?
Prisma is headquartered in Cambridge, United States.
Find investors for your startup like Prisma
Gritt sends AI-personalised outreach to each investor — from your Gmail
